Your Oncology CRO Partner for Every Phase of Drug Development

Overcome complex oncology challenges with Allucent’s dedicated expertise across every phase of development, from early product strategy and preclinical research through clinical development and post-approval.

Get Started with a Customized Clinical Solution

Extensive Oncology and Hematology Experience

We have the hands-on knowledge and expertise to manage the complexities of cancer research and provide full-service support that spans a wide range of oncology and hematology indications.

270+

Studies
4,000+

Sites
24,000+

Patients
40+

Countries

Why Allucent?

At Allucent, we understand the unique challenges in oncology drug development and offer targeted solutions to help you overcome them.

Patient Recruitment

Overcoming stringent eligibility criteria with patient-centric strategies, leveraging global reach, genetic data, and EMRs to accelerate enrollment.

Complex Study Designs

Expertly tailored oncology trials using adaptive, basket, crossover, and single-arm designs, integrating biomarkers for precision medicine.

Cost & Site Management

Avoid site saturation and control costs with strategic site selection, leveraging KOL relationships and feasibility assessments to optimize trial execution.

Regulatory Navigation

Expert guidance from former regulators to streamline compliance, optimize trial design, and navigate fast-track pathways like Project Optimus and Project Orbis.

Expertise Across Solid Tumors

We leverage our deep expertise across solid tumors, hemato-oncology, and hematology to support a broad range of indications. Our comprehensive approach spans both traditional and advanced therapies, ensuring tailored strategies for each treatment type.

Cell and Gene Therapies

Leverage our expertise in Cell and Gene Therapy (CGT) clinical trials, with experience in over 40 studies spanning autologous and allogeneic cell products, NK cells, T-cells, and oncolytic viruses.

Chemotherapies

Proven experience in chemotherapy trials across Phases I-IV, with expertise in combination therapies alongside targeted and immunotherapies to optimize dosing and improve outcomes.

Radiotherapies

Expert support for radiolabeled protein and Radium-223 trials across Phases I-IV, with proven success in regulatory approvals, including NDA and MAA submissions.

Targeted Therapies

Expertise in targeted therapies across 115+ studies, including adaptive trial designs, basket trials, antibodies, small molecules, and FDA approvals.

Hormonal Therapies

Expertise in therapies for hormone-driven cancers, including breast and prostate, with experience in aromatase inhibitors, selective estrogen receptor inhibitors, and combination treatments

Immunotherapies

Expertise in 100+ immuno-oncology studies, combining immunotherapy drugs with chemotherapy and targeted therapies, with proficiency in irRC, iRECIST, and immune-related adverse events.

Speak With an Expert

Testimonial

We recently hired Allucent as our global CRO on an extremely complex cell therapy program in oncology. In the bid process they went above and beyond any CRO I've worked with to respond to questions, collaborate and even advise us to a degree that it seemed like they had thought about the program as much as we had.

LEADING BIOTECH

We benefited greatly from their deep experience and their professional, yet comfortable working relationship. The most impressive part about working with Allucent is that they can be trusted to deliver what they promise.

SENIOR VICE PRESIDENT OF CLINICAL DEVELOPMENT AND MEDICAL AFFAIRS

Given the complexity of the global regulatory landscape and running cell therapy studies, Allucent made available senior staff with FDA experience and a high degree of expertise all around to help us navigate.

LEADING BIOTECH

Oncology and Hematology

We support your oncology and hematology drug development journey at every stage, from preclinical planning to post-marketing success.

Product Development Strategy & Pre-Clinical

Pre-clinical, CMC, and Non-Clinical
Gap/Risk Analysis
Target Product Profile & Indication
Global Regulatory Strategy, Translational Strategy & Modeling

Clinical Development

Protocol Design & Dose Optimization
Phase I-III Clinical Trials
Model Informed Drug Development
CTD Authoring & Submissions

Marketing Authorization & Post-Approval

Phase IV Clinical Studies
Registration & Regulatory Compliance
Pharmacovigilance & Medical Information
Life Cycle Maintenance

Meet Some of Our Oncology and Hematology Experts

Brian Abbott, MD

Executive Medical Director,
Oncology

Brian Barnett, MD

Executive Medical Director,
Oncology

Oksana Fabri, PhD, MD

Sr. Medical Director,
Oncology

Sandra Olthof

Global Operations Head,
Oncology

About Us

A Fully Integrated Global Company

Allucent delivers innovative strategies and robust solutions based on over 30 years of background in regulatory trends, therapeutic experience, and operational expertise. We share small and mid-sized companies’ deep commitment to supporting breakthrough science by partnering with them to navigate the complexities of delivering novel treatments to patients.

With offices across North America, Europe, and the Middle East, Allucent has experience conducting trials in more than 75 countries, focusing on some of the most complex development areas. Globally, Allucent has worked on more than 825 clinical trials, with oncology representing the majority.

Explore